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Subclinical Cushing’s syndrome (SCS) is a condition of slight but chronic cortisol excess in patients with adrenal incidentaloma
(AI) without typical signs and symptoms of Cushing’s syndrome. Adiponectin has potent roles in modulating energy balance
and metabolic homeostasis and acts in opposition to glucocorticoids. This study aimed to evaluate adiponectin level in SCS
and nonfunctional AI (NAI) patients and its relation with metabolic parameters. Patients with AI (𝑛 = 40) and metabolically
healthy controls (𝑛 = 30) were included. In AI patients and controls, detailed medical history assessment, physical examinations,
anthropometric measurements, and laboratory measurements were performed. Age, body mass index, waist circumference, and
lipid profiles were significantly higher and waist-to-hip ratio and adiponectin level were significantly lower in the AI patients than
in the controls. The midnight cortisol and urinary free cortisol levels were significantly higher in the SCS patients (𝑛 = 8) than in
the NAI patients (𝑛 = 32). Adiponectin level of the SCS group was significantly lower than those of the NAI and control groups.
The sensitivity and specificity for an adiponectin level of ≤13.00 ng/mL in predicting the presence of SCS were 87.5% and 77.4%,
respectively. In conclusion, adiponectin is valuable in predicting the presence of SCS in AI patients.
1. Introduction
Adrenal incidentaloma (AI) is an adrenal mass that is typi-
cally discovered serendipitously during radiologic examina-
tions performed for unrelated reasons [1]. AI is observed in
approximately 5% of all abdominal computed tomography
(CT) scans and its prevalence in the general population has
been estimated as 3%–7% [2]. The prevalence of AI increases
with age; the likelihood of encountering an AI on CT is 10%
in patients aged 70 years and older [3].
Most of the AIs are benign adenomas and do not exhibit
hyperfunction [2]. Nevertheless, pheochromocytoma, aldos-
teronism, or overt cortisol excess due to hyperfunction can
be observed in patients with AI [4]. Autonomous cortisol (a
glucocorticoid hormone) secretion in patients with features
similar to Cushing’s syndrome (CS) such as obesity, hyper-
tension, glucose intolerance, and osteoporosis but without
typical signs or symptoms of hypercortisolism is defined as
subclinical CS (SCS) [4–6]. The clinical presentation of CS
varies according to the extent and duration of cortisol hyper-
secretion; however, proximal muscle wasting, wide purple
striae, and easy bruising are the unique signs of CS. Specif-
ically, patients with hypercortisolism usually present with
central obesity, a round and erythematous face, supraclavic-
ular fat pads, cervical fat accumulation called buffalo hump,
thinning of the skin, and proximalmuscleweakness [7–10]. In
patients with SCS, slight but chronic cortisol release has been
associated with increased cardiovascular risks and metabolic
syndrome [11, 12]. SCS diagnosis is established via abdominal
CT scan in patients having an incidental adrenal mass, with-
out the above-mentioned typical physical features of CS, and
exhibiting endogenous hypercortisolism in hormonal tests.
Nevertheless, there are no universally accepted hormonal cri-
teria for SCS diagnosis [6, 13–16]. A cortisol value of>5 𝜇g/dL
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after 1-mg dexamethasone suppression test (1-mg DST) is
accepted as a sufficient criterion to diagnose SCS [15–17].
Patients with cortisol values between 1.8 𝜇g/dL and 5 𝜇g/dL
in this test should also have at least one other criterion:
lack of circadian cortisol secretion rhythm (late evening to
morning serum cortisol % ratio exceeded 50%), decreased
morning adrenocorticotropic hormone (ACTH) concentra-
tion (≤10 pg/mL), and/or increased 24-hour urinary free
cortisol excretion [15–17].
Adiponectin, a peptide with 244 amino acids, is a very
important hormone that is secreted primarily fromwhite adi-
pose tissue. Adiponectin is involved in metabolic processes
and negatively correlates with obesity [18]. Glucocorticoids
and adiponectin play opposing roles in regulating energy
metabolism, where glucocorticoids activate catabolic pro-
cesses and insulin resistance. Adiponectin acts primarily as
an insulin sensitizer [18, 19]. There is growing evidence that
adiponectin has protective effects against type 2 diabetesmel-
litus [20]. Additionally, with respect to immune and inflam-
matory processes, both glucocorticoids and adiponectin have
anti-inflammatory effects [21, 22].Thus, there is an increasing
interest in the clinical application of adiponectin on vari-
ety of diseases such as dyslipidemia, metabolic syndrome,
hypertension, and cancer (breast, colon, andprostate cancers)
[23]. Drugs enhancing endogenous adiponectin production
or using recombinant adiponectin attract attention as the
potential treatment targets [24].
It is known that the metabolic abnormalities of SCS
remain elusive [25]. Surgical removal of autonomously corti-
sol-secreting adenoma has beneficial effects on blood pres-
sure and insulin sensitivity [26, 27]; however, there are still
insufficient data to support routine adrenalectomy in the
clinical setting [28]. In a study, the patients with CS were
observed to have low adiponectin levels; however, obesity was
reported to mask the relationship between adiponectin and
cortisol [29].The present study aimed to evaluate adiponectin
levels in patients with SCS and nonfunctional AI (NAI) and
its relation with metabolic parameters.
2. Materials and Methods
2.1. Subjects. Patients (𝑛 = 40) referred to the Endocrinology
and Metabolic Disease Outpatient Clinic for incidentally
discovered adrenalmasses were included in the present study.
The control group included metabolically healthy subjects
(𝑛 = 30) without adrenal adenomas or hyperplasia. Patients
with type 1 diabetes mellitus, uncontrolled hypertension,
chronic renal failure, chronic hepatic disease, depression,
or alcoholism or those who were on medication that could
influence insulin, cortisol, and dexamethasone metabolisms
or cortisol secretion were excluded from the study. All the
patients diagnosed with type 2 diabetes mellitus were newly
diagnosed patients andnot on any antidiabetic treatment.The
patients included in the present study were not using statins
for about 12 weeks.
In AI patients and controls, detailed medical history
assessment, physical examinations, and anthropometricmea-
surements were performed. Blood samples were obtained at
08:00 a.m. for the measurements of basal cortisol, ACTH,
dehydroepiandrosterone sulfate (DHEAS), fasting blood glu-
cose (FBG), and insulin levels as well as lipid profiles and
adiponectin levels. Additionally, 24-hour urinary cortisol
excretion and midnight cortisol level were measured and 1-
mg DST was performed in the SCS and NAI patients.
The study was approved by the Baskent University
Institutional Review Board and Ethics Committee (Project
number KA07/69) (Ethics Committee for Baskent University
Hospitals) and conducted in accordance with the Declaration
of Helsinki II. All participants provided written informed
consent before participating in the study.
2.2. Measurements. All incidentalomas discovered by abdo-
minal ultrasound ormagnetic resonance imaging (MRI)were
evaluated by CT. On CT, all adrenal masses were homoge-
nous, hypodense, and well shaped which were the features
consistent with the diagnosis of adrenocortical adenoma. No
patient had evidence of metastatic disease. In each patient,
three diameters of the adrenal mass were measured and the
largest diameter was recorded.
The 24-hour urinarymetanephrines and the aldosterone-
to-renin ratio were within normal ranges in AI patients,
thus excluding pheochromocytoma and aldosteronoma. All
AI patients with hypertension initiated verapamil 6 weeks
before functional evaluation. None of the patients had overt
signs or symptoms of CS. The diagnosis of SCS was based
on the presence of at least one of the following in addition
to cortisol levels greater than 1.8𝜇g/dL after 1-mg DST [13]:
(1) urinary free cortisol (UFC) levels of >300 𝜇g/day in two
of the three consecutive collections per 24-hour period, (2)
ACTH levels of <10 pg/mL (<2.2 pmol/L), and (3) low serum
DHEAS levels.
The body mass index (BMI) was calculated as weight
in kilograms divided by height in meters square (kg/m2).
The waist-to-hip ratio was calculated as the ratio between
the smallest circumference of the torso and the maximum
circumference of the hips over the buttocks. Body composi-
tion was measured by bioelectrical impedance analysis using
the TANITA TBF-300 Body Composition Analyzer (Tanita
Corp., Tokyo, Japan). Anthropometric measurements were
obtained using standardized equipment and following the
recommendations of the International Biological Program.
Serum cortisol, UFC, andDHEAS levels were determined
using commercial radioimmunoassay (RIA) kits (Immulite
2000; Diagnostic Products Corp., Los Angeles, CA, USA).
ACTH levels were measured using an immunoradiometric
assay (IRMA) (Immulite 2000).The 24-hour urine-fractiona-
ted metanephrines and vanillylmandelic acid (VMA) were
measured using high-pressure liquid chromatography, in
which the container was acidified with 10mL to 25mL of
6N HCl for the preservation of the metanephrines. Before
urine collections for VMA testing, patients were asked to
avoid salicylates, caffeine, tea, chocolate, bananas, and vanilla
for 72 hours. Plasma aldosterone concentrations (PAC) were
measured by RIA and quantitative determination of plasma
renin activity (PRA) was done by the enzyme-linked immu-
nosorbent assay (ELISA). The blood sample was collected in
a tube containing ethylenediaminetetraacetic acid.The lower
limit of the assay for the detection of PRA was 0.1 ng/mL/h.
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The cut-off value for PAC (in ng/dL)/PRA (in ng/mL/h) ratio
was accepted as 20 for hyperaldosteronism.
For the measurement of FBG, an enzymatic colorimetric
method with glucose oxidase was used. Lipid profiles, includ-
ing triglycerides, high-density lipoprotein cholesterol (HDL-
C), and low-density lipoprotein cholesterol (LDL-C), were
assessed using commercially available assay kits (RocheDiag-
nostics, GmbH Roche Molecular Biochemicals, Mannheim,
Germany). Insulin levels were measured using the Immulite
2000 immunoassay analyzer (Euro/DPC, Llanberis, UK).The
HOMA-IR was estimated according to the following formula
[30]: HOMA-IR = [FBG (mmol/L) × Fasting insulin level
(mU/L)]/22.5.
Adiponectin levels were measured in duplicate using
a commercially available ELISA kit (Linco Research, St.
Charles, MO, USA). The sensitivity of the assay was 0.78 ng/
mL. The intra-assay and interassay coefficients of variation
were less than 7.4% and 8.4%, respectively.
2.3. Statistical Analyses. Data analyses were performed using
the PASW Statistics for Windows, version 18.0 (SPSS Inc.,
Chicago, IL, USA). Descriptive statistics were expressed as
number and percentage for categorical variables and as
mean, standard deviation, median, 25th percentile (𝑄1), 75th
percentile (𝑄3), and minimum and maximum for numerical
variables. For the comparisons of independent numerical
variables, when normal distribution assumption was notmet,
Mann–Whitney 𝑈 test was used for two group compar-
isons and Kruskal-Wallis test was used for multiple group
comparisons. For subgroup analyses, Mann–Whitney 𝑈 test
was performed with the Bonferroni correction. Chi-square
test was used for between-group comparisons of categorical
variables. In order to determine the relationship between
adiponectin level and numerical variables, Spearman’s rho
test was used when normal distribution assumption was not
met. The receiver operating characteristics (ROC) analysis
was used to determine the value of adiponectin level in pre-
dicting the presence ofAI and SCS.The statistical significance
was evaluated at a type 1 error of<5%.The independent effects
of age, gender, waist circumference, hip circumference, waist-
to-hip ratio, body fat percentage, fat-freemass (FFM), insulin,
HOMA-IR, LDL-C, HDL-C, triglyceride, and study group
variables, which yielded a 𝑝 value of <0.200, on adiponectin
were investigated by performing multivariate linear regres-
sion analysis. Thereafter, a model including age, gender, hip
circumference,HOMA-IR, LDL-C, and study group variables
was developed. For linear regression analysis, a logarithmic
transformation was performed for adiponectin levels.
3. Results
The present study included 40 AI patients (24 females and
16 males) with a mean age of 60.5 ± 8.2 years (range, 45–76
years). The control group included 30 subjects (22 females
and 8 males) with a mean age of 26.0 ± 4.4 years.
The clinical, demographic, and metabolic characteristics
of theAI patients and controls are shown inTable 1. Age, BMI,
waist circumference, and levels of total cholesterol, LDL-C,
12.0
24.4
39.4
NAI ControlSCS
Groups
0
5
10
15
20
25
30
35
40
45
Ad
ip
on
ec
tin
 le
ve
l (
ng
/m
L)
Figure 1: Adiponectin levels in the study groups. SCS, subclinical
Cushing’s syndrome; NAI, nonfunctional adrenal incidentaloma.
HDL-C, and triglyceride were significantly higher and waist-
to-hip ratio and adiponectin level were significantly lower in
the AI patients than in the controls.
Among the AI patients, 8 (20%) were diagnosed with SCS
and the remaining patients (80%) were classified as NAI.The
hormonal profiles and the diameters of adrenal adenomas in
the SCS and NAI patients are shown in Table 2.Themidnight
cortisol and UFC levels were significantly higher in the SCS
patients than in theNAI patients. Of the 8 patientswith SCS, 5
had high midnight cortisol levels, 3 had high urinary cortisol
excretion, and 4 had low DHEAS levels. The patients with
ACTH levels >10 pg/mL were evaluated using pituitary MRI
and no pituitary adenomas were detected.
Comparison of the SCS,NAI, and control groups revealed
that age, BMI, waist circumference, insulin levels, HOMA-
IR, lipid profiles, and adiponectin levels were significantly
differed among the groups (Table 3).
Two group comparisons revealed that only adiponectin
level was significantly lower in the SCS group than in the
NAI group (𝑝 = 0.007); there was no significant difference
between the two groups in terms of other parameters. Age
(𝑝 = 0.001), insulin level (𝑝 = 0.002), and HOMA-IR (𝑝 =
0.003) were significantly higher and adiponectin level (𝑝 <
0.001) was significantly lower in the SCS group than in the
control group. Age (𝑝 < 0.001), BMI (𝑝 = 0.003), waist
circumference (𝑝 < 0.001), and the levels of total cholesterol
(𝑝 < 0.001), LDL-C (𝑝 = 0.006), HDL-C (𝑝 = 0.010), and
triglyceride (𝑝 = 0.001) were significantly higher in the NAI
group than in the control group. Insulin levels, HOMA-IR,
and adiponectin levels were similar in the NAI and control
groups. As a result, the adiponectin level of the SCS group
was significantly lower than those of both NAI and control
groups (Figure 1).
Adiponectin level was significantly and negatively asso-
ciated with insulin level, HOMA-IR, triglyceride level, FFM,
and midnight cortisol level and it was significantly and
positively associated with body fat percentage and HDL-C
and ACTH levels (Table 4). The linear regression analysis
conducted to determine the risk factors affecting adiponectin
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Table 1: Demographic, clinical, and metabolic characteristics of the adrenal incidentaloma patients and control subjects.
Patients with AI
(𝑛 = 40)
Control subjects
(𝑛 = 30) 𝑝
𝑛 (%) 𝑛 (%)
Gender
Female 24 (60.0) 22 (73.3) 0.245
Male 16 (40.0) 8 (26.7)
Median (𝑄1–𝑄3) Median (𝑄1–𝑄3)
Age, years 60 (55.5–65.5) 32 (24–44) <0.001
Body mass index, kg/m2 29.1 (25.8–31.7) 25.8 (22.8–28.3) 0.004
Waist circumference, cm 97 (90.5–104) 85 (83–90) <0.001
Waist-to-hip ratio 0.90 (0.85–0.94) 0.93 (0.92–0.95) 0.049
Body fat percentage, % 33.9 (24.6–41.9) 29.1 (26.0–33.0) 0.097
Fat-free mass, kg 48.6 (44.9–55.9) 44.8 (41.1–56.8) 0.151
FBG, mg/dL 93.5 (88–110) 91 (88–97) 0.147
Insulin, 𝜇IU/mL 8.8 (5.6–11.2) 6.6 (4.8–8.1) 0.055
HOMA-IR 1.94 (1.38–2.47) 1.50 (1.20–1.98) 0.079
Total cholesterol, mg/dL 219.6 (187.4–249.8) 173.2 (158.4–187.6) <0.001
LDL-C, mg/dL 132.0 (101.0–156.0) 106.5 (94.0–120.0) 0.006
HDL-C, mg/dL 52.0 (42.0–67.0) 46.0 (38.0–52.0) 0.044
Triglycerides, mg/dL 133.0 (102.0–189.0) 83.5 (66.0–118.0) <0.001
Adiponectin, ng/mL 15.6 (11.7–48.3) 39.3 (25.9–44.1) 0.034
AI, adrenal incidentaloma; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol.
Table 2: Hormonal profiles and adenoma diameters of the patients with adrenal incidentaloma.
Patients with AI
𝑝Patients with SCS Patients with NAI
Median (𝑄1–𝑄3) Median (𝑄1–𝑄3)
Adenoma diameter, cm 3.05 (2.25–3.55) 1.85 (1.60–3.00) 0.154
Basal cortisol at 08:00 a.m., 𝜇g/dL 16.30 (13.20–24.65) 17.05 (12.40–21.25) 0.554
Midnight cortisol, 𝜇g/dL 9.15 (7.00–12.25) 5.10 (3.80–7.80) 0.004
ACTH, pg/mL 9.25 (8.60–12.00) 10.70 (8.55–13.00) 0.612
DHEAS, mg/dL 22.10 (15.00–41.95) 51.65 (42.00–113.00) 0.054
UFC, 𝜇g/24 h 249 (215–366) 170 (140–220) 0.007
AI, adrenal incidentaloma; SCS, subclinical Cushing’s syndrome; NAI, nonfunctional adrenal incidentaloma; ACTH, adrenocorticotropic hormone; DHEAS,
dehydroepiandrosterone sulfate; UFC, urinary free cortisol.
level in amodel including age, male gender, HOMA-IR, LDL-
C, waist circumference, and presence of SCS revealed that
age was a significant increasing factor, whereas male gender,
HOMA-IR, LDL-C,waist circumference, and presence of SCS
were significant decreasing factors (Table 5).
Evaluation of the ROC analysis revealed that adiponectin
level had a predictive value in determining the presence of
AI (area under the curve (AUC): 0.65, confidence interval
(CI): 0.52–0.78, and 𝑝 = 0.034). The sensitivity, specificity,
positive predictive value, and negative predictive value for an
adiponectin level of ≤22.07 ng/mL in predicting the presence
of AI were 54.6%, 83.3%, 81.5%, and 59.5%, respectively
(Figure 2).
Evaluation of the ROC analysis also revealed that
adiponectin level had a predictive value in determining
the presence of SCS (AUC: 0.81, CI: 0.67–0.96, and 𝑝 =
0.007). The sensitivity, specificity, positive predictive value,
and negative predictive value for an adiponectin level of
≤13.00 ng/mL in predicting the presence of SCS were 87.5%,
77.4%, 50.0%, and 96.0%, respectively (Figure 3).
4. Discussion
Histologically, AIs are mostly adrenocortical adenomas. Of
these cases, approximately 1.7% develop hyperfunction and
the risk is higher in the lesions greater than 3 cm [31].
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Table 3: Demographic, clinical, and metabolic characteristics of the study groups.
SCS group
(𝑛 = 8)
NAI group
(𝑛 = 32)
Control group
(𝑛 = 30) 𝑝
𝑛 (%) 𝑛 (%) 𝑛 (%)
Gender
Female 5 (62.5) 19 (59.4) 22 (73.3) 0.501
Male 3 (37.5) 13 (40.6) 8 (26.7)
Median (𝑄1–𝑄3) Median (𝑄1–𝑄3) Median (𝑄1–𝑄3)
Age, years 56.5 (51.5–64) 61 (56–66) 32 (24–44) <0.001
Body mass index, kg/m2 26.8 (25.0–31.5) 29.4 (26.4–31.9) 25.8 (22.8–28.3) 0.012
Waist circumference, cm 96 (85.5–100.5) 97.5 (91.5–104.5) 85 (83–90) <0.001
Waist-to-hip ratio 0.91 (0.81–0.98) 0.90 (0.86–0.94) 0.93 (0.92–0.95) 0.138
Body fat percentage, % 27.7 (21.5–35.1) 34.8 (25.8–43.6) 29.1 (26.0–33.0) 0.075
Fat-free mass, kg 49.9 (46.3–56.0) 48.4 (44.5–55.9) 44.8 (41.1–56.8) 0.272
FBG, mg/dL 95 (84–121) 93.5 (88.5–107.5) 91 (88–97) 0.338
Insulin, 𝜇IU/mL 13.3 (10.0–15.5) 7.9 (4.5–9.8) 6.6 (4.8–8.1) 0.009
HOMA-IR 2.76 (2.07–4.17) 1.73 (1.01–2.08) 1.50 (1.20–1.98) 0.018
Total cholesterol, mg/dL 193.2 (179.6–223.8) 221 (187.4–251.6) 173.2 (158.4–187.6) 0.001
LDL-C, mg/dL 125.0 (108.0–134.5) 139.0 (101.0–162.0) 106.5 (94.0–120.0) 0.014
HDL-C, mg/dL 42.0 (41.5–47.5) 54.0 (44.0–68.0) 46.0 (38.0–52.0) 0.018
Triglycerides, mg/dL 135.5 (103.5–241.0) 133.0 (102.0–165.0) 83.50 (66.0–118.0) 0.002
Adiponectin, ng/mL 12.0 (7.3–12.8) 24.4 (13.1–48.8) 39.4 (25.9–44.1) 0.001
SCS, subclinical Cushing’s syndrome; NAI, nonfunctional adrenal incidentaloma; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment of
insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
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Figure 2: Receiver operating characteristics (ROC) curve for
adiponectin level in predicting the presence of adrenal inciden-
taloma (AI).
Cortisol hypersecretion is the most frequently encountered
hyperfunction and progresses subclinically in approximately
two-thirds of the cases [31]. In various studies, the fre-
quency of SCS has been reported as 5%–47% in AI patients
Se
ns
iti
vi
ty
0.2 0.4 0.6 0.8 1.00.0
1 − specificity
0.0
0.2
0.4
0.6
0.8
1.0
Figure 3: Receiver operating characteristics (ROC) curve for
adiponectin level in predicting the presence of subclinical Cushing’s
syndrome (SCS).
depending on the study protocol and diagnostic criteria [32].
In the present study, in selected AI patients with benign
adrenal lesions and without evidence of hyperaldosteronism
or pheochromocytoma, the frequency of SCS was 20%. The
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Table 4: Relationship of adiponectin with other parameters.
Adiponectin
𝑛 rho 𝑝
Age 69 –0.077 0.532
Adenoma diameter 39 –0.166 0.312
Body mass index 69 –0.017 0.892
Fasting blood glucose 69 –0.098 0.421
Insulin 58 –0.387 0.003
HOMA-IR 58 –0.391 0.002
Total cholesterol 65 –0.191 0.127
LDL-C 66 –0.235 0.057
HDL-C 65 0.386 0.001
Triglycerides 66 –0.504 <0.001
Body fat percentage 69 0.294 0.014
Fat-free mass 69 –0.502 <0.001
Waist circumference 69 –0.23 0.057
Waist-to-hip ratio 69 –0.159 0.192
Basal cortisol 69 –0.112 0.361
Midnight cortisol 39 –0.359 0.025
ACTH 65 0.284 0.022
UFC 25 –0.372 0.067
DHEAS 36 –0.402 0.015
HOMA-IR, homeostasis model assessment of insulin resistance; LDL-
C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; ACTH, adrenocorticotropic hormone; UFC, urinary free corti-
sol; DHEAS, dehydroepiandrosterone sulfate.
Table 5: Risk factors affecting the adiponectin level.
𝐵 or coefficients 𝑝
Constant 5.748 <0.001
Age 0.012 0.066
Gender −0.708 0.001
HOMA-IR −0.229 0.024
LDL-C −0.005 0.068
Waist circumference −0.019 0.114
SCS −1.009 0.005
Adiponectin= 5.748+ 0.012∗ age+ (−0.229)∗HOMA-IR+ (−0.005)∗LDL-
C + (−0,019) ∗ waist circumference + (−1,009) ∗ SCS + (−0,708) ∗ gender
(male).
HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C,
low-density lipoprotein cholesterol; SCS, subclinical Cushing’s syndrome.
median adenoma diameter in the patients with SCS was
3.05 cm. The midnight cortisol level (median 9.15 versus
5.10 𝜇g/dL, 𝑝 = 0.004) and the UFC level (median 249 versus
170 𝜇g/24 h, 𝑝 = 0.007) were significantly higher in the SCS
patients than in the NAI patients.
Chronic release of glucocorticoids is associated with
cardiovascular risk factors including abdominal obesity,
insulin resistance, impaired glucose tolerance, diabetes melli-
tus, atherosclerosis, systemic hypertension, and dyslipidemia
[33–37]. As these factors strongly affect morbidity and
mortality, awareness of SCS is of importance. Conflicting
results regarding decreased insulin sensitivity inNAI patients
compared with SCS patients have been reported [12, 35, 38].
In the present study, the HOMA-IR and insulin level of the
SCS patients were significantly higher than the controls. The
lipid levels, BMI, and waist circumference were significantly
higher in the NAI patients than in the controls. These
parameters were also higher in the SCS group than in the
controls; however, the difference did not reach statistical
significance. This finding might be resulting from the small
number of the patients in the SCS group. Elevated midnight
cortisol concentration (>5 𝜇g/dL) has been reported as a
marker of increased cardiovascular risk in AI patients [39].
In the present study, while the midnight cortisol level was
5.10 𝜇g/dL in the NAI patients, it was 9.15 𝜇g/dL in the SCS
patients and the difference was statistically significant.
Adipose tissue secretes a number of cytokines and
bioactive compounds, which are called adipokines, leading
to metabolic alterations and cardiovascular morbidity [40].
Adiponectin is an adipokine that is primarily produced by
visceral fat and circulates in the blood in different forms of
varying molecular weights [41]. A low level of adiponectin
is a common feature of obesity and is associated with
insulin resistance [42]. Adiponectin also plays an important
role in the development of cardiovascular risk by affecting
proinflammatory molecules [43]. Although there are stud-
ies investigating the association between adiponectin and
glucocorticoids, the results are inconclusive due to differ-
ent transcription factors, signaling cascades, and hormones
that regulate adiponectin expression [44]. Glucocorticoids
regulate many different genes, signaling cascades, and tran-
scription factors, some of which can regulate adiponectin
expression [45, 46]. Although increased cardiovascular risk
factors are observed in SCS patients, no standard treatment
strategies exist. Therefore, we evaluated adiponectin levels
in SCS patients. To the best of our knowledge, this is the
first study to evaluate adiponectin levels in the SCS patients.
As we hypothesized, we found the adiponectin levels to be
lower in the SCS patients. The adiponectin levels of the SCS
patients (12.0 ng/mL) were significantly lower than those of
the NAI patients (24.4 ng/mL) and controls (39.4 ng/mL). In
the present study, adiponectin level was found to be positively
correlated with ACTH and HDL-C and negatively correlated
with insulin, HOMA-IR, triglyceride, FFM, and midnight
cortisol levels in all participants included in the present study.
In a study, the adiponectin level was reported to be higher
in the NAI patients than in the healthy controls and not
related to the visceral obesity and it was hypothesized that
adiponectin might be produced from the adrenal gland [47].
In the present study, adiponectin level was lowest in the
SCS group and highest in the healthy control group, with a
statistically significant difference between the SCS group and
controls. Accordingly, we did not think that adiponectin was
originated from the adrenal glands. In addition, we did not
find a correlation between altered hypophysis-adrenal axis
and adiponectin levels. In the study by Wallia et al. [48],
adiponectin level was significantly increased with mifepris-
tone throughout the course of treatment in the patients with
CS. This finding also supports our result of low adiponectin
level in the SCS patients.
In the present study, a ROC analysis was performed to
determine the value of adiponectin in predicting the presence
International Journal of Endocrinology 7
of AI and SCS. Accordingly, we found that the sensitivity,
specificity, positive predictive value, and negative predictive
value for an adiponectin level of ≤22.07 ng/mL in predicting
the presence of AI were found as 54.6%, 83.3%, 81.5%, and
59.5%, respectively. The sensitivity, specificity, positive pre-
dictive value, and negative predictive value for an adiponectin
level of ≤13.00 ng/mL in predicting the presence of SCS were
found as 87.5%, 77.4%, 50.0%, and 96.0%, respectively.
5. Conclusions
To the best of our knowledge, this is the first study demon-
strating low levels of adiponectin in patients with SCS. Pres-
ence of SCS should be considered in case of an adiponectin
level of ≤13.00 ng/mL in AI patients. Low adiponectin levels
in SCS patients may be important in treatment decision due
to the known relation between adiponectin and cardiovascu-
lar events. In order to increase the evidences on this subject,
further prospective follow-up studies with larger number of
subjects are needed.
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